Current Rheumatology Reports

, 15:384 | Cite as

Osteopenia: Debates and Dilemmas

OSTEOPOROSIS AND METABOLIC BONE DISEASE (KG SAAG, SECTION EDITOR)
Part of the following topical collections:
  1. Topical Collection on Osteoporosis and Metabolic Bone Disease

Abstract

Whether or not to use pharmacologic agents for primary prevention of fracture among elderly men and women with osteopenia is debated by clinicians. In this review we provide an update to enable better understanding and characterization of this population, including the prevalence of osteopenia, transitioning from osteopenia to osteoporosis, and clinically applicable tools for fracture risk assessment. We also emphasize the very limited evidence of the benefits and risks of anti-osteoporotic agents for this population for primary fracture prevention, and the need for future studies to guide clinical practice.

Keywords

Osteopenia Pharmacologic treatment Debates Epidemiology Fracture risk FRAX Adverse events 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Kanis JA, Melton 3rd LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137–41.PubMedCrossRefGoogle Scholar
  2. 2.
    Leslie WD, Adler RA, El-Hajj Fuleihan G, et al. Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions. J Clin Densitom. 2006;9(1):22–30.PubMedCrossRefGoogle Scholar
  3. 3.
    Looker AC, Melton 3rd LJ, Harris TB, Borrud LG, Shepherd JA. Prevalence and trends in low femur bone density among older US adults: NHANES 2005–2006 compared with NHANES III. J Bone Miner Res. 2010;25(1):64–71.PubMedCrossRefGoogle Scholar
  4. 4.
    Looker AC, Orwoll ES, Johnston Jr CC, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12(11):1761–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Donaldson MG, Cawthon PM, Lui LY, et al. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res. 2009;24(4):675–80.PubMedCrossRefGoogle Scholar
  6. 6.
    Donaldson MG, Cawthon PM, Lui LY, et al. Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res. 2010;25(7):1506–11.PubMedCrossRefGoogle Scholar
  7. 7.
    Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med. Mar 1 2011;154(5):356–364.Google Scholar
  8. 8.
    Lewiecki EM, Gordon CM, Baim S, et al. International society for clinical densitometry 2007 adult and pediatric official positions. Bone. 2008;43(6):1115–21.PubMedCrossRefGoogle Scholar
  9. 9.
    • Gourlay ML, Fine JP, Preisser JS, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366(3):225–33. This article suggests there is significant variability in the risk of development of osteoporosis among osteopenic women irrespective of baseline bone density.PubMedCrossRefGoogle Scholar
  10. 10.
    Frost SA, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Timing of repeat BMD measurements: development of an absolute risk-based prognostic model. J Bone Miner Res. 2009;24(11):1800–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Hillier TA, Cauley JA, Rizzo JH, et al. WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis? J Bone Miner Res. 2011;26(8):1774–82.PubMedCrossRefGoogle Scholar
  12. 12.
    Cranney A, Jamal SA, Tsang JF, Josse RG, Leslie WD. Low bone mineral density and fracture burden in postmenopausal women. CMAJ. 2007;177(6):575–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164(10):1108–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34(1):195–202.PubMedCrossRefGoogle Scholar
  15. 15.
    Miller PD, Barlas S, Brenneman SK, et al. An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med. 2004;164(10):1113–20.PubMedCrossRefGoogle Scholar
  16. 16.
    Berry SD, Kiel DP, Donaldson MG, et al. Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study. Osteoporos Int. 2010;21(1):53–60.PubMedCrossRefGoogle Scholar
  17. 17.
    McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol. 2009;114(5):999–1007.PubMedCrossRefGoogle Scholar
  18. 18.
    Chapurlat RD, Laroche M, Thomas T, Rouanet S, Delmas PD, de Vernejoul MC. Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia—a randomized placebo-controlled trial. Osteoporos Int. 2013;24(1):311–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Valimaki MJ, Farrerons-Minguella J, Halse J, et al. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial. Clin Ther. 2007;29(9):1937–49.PubMedCrossRefGoogle Scholar
  20. 20.
    Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077–82.PubMedCrossRefGoogle Scholar
  21. 21.
    McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333–40.PubMedCrossRefGoogle Scholar
  22. 22.
    Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290(13):1729–38.PubMedCrossRefGoogle Scholar
  23. 23.
    McCloskey EV, Beneton M, Charlesworth D, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res. 2007;22(1):135–41.PubMedCrossRefGoogle Scholar
  24. 24.
    Tosteson AN, Melton 3rd LJ, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19(4):437–47.PubMedCrossRefGoogle Scholar
  25. 25.
    Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med. 2005;142(9):734–41.PubMedCrossRefGoogle Scholar
  26. 26.
    Meadows ES, Klein R, Rousculp MD, Smolen L, Ohsfeldt RL, Johnston JA. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health. 2007;7:6.PubMedCrossRefGoogle Scholar
  27. 27.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.PubMedCrossRefGoogle Scholar
  28. 28.
    Zhang J, Saag KG, Curtis JR. Long-term safety concerns of antiresorptive therapy. Rheum Dis Clin N Am. 2011;37(3):387–400. vi.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of EpidemiologyUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Division of Clinical Immunology and RheumatologyUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations